Neuroactive substituted cyclopent[a]anthracenes as modulators for GABA type-A receptors

US9562026B2 · US · B2

Patent metadata
FieldValue
Publication numberUS-9562026-B2
Application numberUS-201414203678-A
CountryUS
Kind codeB2
Filing dateMar 11, 2014
Priority dateMar 14, 2013
Publication dateFeb 7, 2017
Grant dateFeb 7, 2017

How to read this patent

A practical reading order for non-experts. Skip the full description unless you need deep technical detail.

  1. Title

    What the patent document calls the invention.

  2. Abstract

    A short plain-language summary of the technical disclosure.

  3. Assignees and inventors

    Who owns or filed the patent and who is credited as inventor.

  4. Key dates

    Filing, priority, publication, and grant dates set the timeline.

  5. First independent claim

    The legal scope of protection — read this for what is actually claimed.

  6. CPC / IPC classifications

    Technology tags used to group this patent with similar filings.

  7. Citations and related patents

    Prior art links and similar publications in this corpus.

Abstract

Official abstract text for this publication.

The present disclosure is generally directed to neuroactive substituted cyclopent[a]anthracenes as referenced herein, and pharmaceutically acceptable salts thereof, for use as, for example, an anesthetic, and/or in the treatment of disorders relating to GABA function and activity. The present disclosure is further directed to pharmaceutical compositions comprising such compounds.

First claim

Opening claim text (preview).

What is claimed is: 1. A compound of Formula (I): or a pharmaceutically acceptable salt thereof; wherein: R 1 is H, R 2 is H, R 3 is H, ═O, ═CHCN, ═CHCO 2 R t , where R t is optionally substituted C 1 -C 4 alkyl, optionally substituted C 2 -C 4 alkenyl, or optionally substituded C 2 -C 4 alkynyl, —CN, β-OH, β-OR s , where R s is optionally substituted C 1 -C 4 alkyl, optionally substituted C 2 -C 4 alkenyl, or optionally substituted C 2 -C 4 alkynyl, β-NO 2 , spiroepoxy, or C(O)R r , where R r is optionally substituted C 1 -C 4 alkyl, optionally substituted C 2 -C 4 alkenyl, or optionally substituted C 2 -C 4 alkynyl; R 4 is methyl; R 5 is H, R 6 is H, R 7 is H, R 8 is H, R 9 is H, optionally substituted C 1 -C 4 alkyl, optionally substituted C 2 -C 4 alkenyl, optionally substituted C 2 -C 4 alkynyl, or optionally substituted aryl; R 10 is H, R 11 is H or C(O)R e , where R e is optionally substituted C 1 -C 20 alkyl, optionally substituted C 2 -C 20 alkenyl, or optionally substituted C 2 -C 20 alkynyl; and, - - - denotes an optional double bond with the proviso that when present R 3 is not ═O, ═CHCN or ═CHCO 2 R t . 2. The compound of claim 1 , wherein R 11 is H. 3. The compound of claim 1 , wherein R 3 is ═O. 4. The compound of claim 1 , wherein R 3 is spiroepoxy. 5. The compound of claim 1 , wherein R 3 is β-CN. 6. The compound of claim 1 , wherein a double bond is present between C 2 -C 3 . 7. The compound of claim 6 , wherein R 3 is —CN. 8. The compound of claim 1 , having the structure (I-a): wherein R 3 is ═O, ═CHCN, ═CHCO 2 R t , where R t is optionally substituted C 1 -C 4 alkyl, optionally substituted C 2 -C 4 alkenyl, or optionally substituted C 2 -C 4 alkynyl, —CN, β-OH, β-OR s , where R s is optionally substituted C 1 -C 4 alkyl, optionally substituted C 2 -C 4 alkenyl, or optionally substituted C 2 -C 4 alkynyl, β-NO 2 , spiroepoxy, or C(O)R r , where R r is optionally substituted C 1 -C 4 alkyl, optionally substituted C 2 -C 4 alkenyl, or optionally substituted C 2 -C 4 alkynyl; and, - - - denotes an optional double bond, with the proviso that when present, R 3 is not ═O, ═CHCN or ═CHCO 2 R t . 9. The compound of claim 1 having the structure: or a pharmaceutically acceptable salt thereof. 10. The compound of claim 1 having the structure: or a pharmaceutically acceptable salt thereof. 11. The compound of claim 1 having the structure: or a pharmaceutically acceptable salt thereof. 12. The compound of claim 1 having the structure: or a pharmaceutically acceptable salt thereof. 13. A pharmaceutical composition comprising the compound of claim 1 , a pharmaceutically acceptable salt thereof, or a combination of two or more thereof, and a pharmaceutically acceptable carrier. 14. A method of inducing anesthesia in a subject in need thereof, said method comprising administering to the subject a therapeutically effective amount of the compound of claim 1 , or a pharmaceutically acceptable salt thereof.

Assignees

Inventors

Classifications

  • containing only six-membered rings · CPC title

  • containing four condensed rings · CPC title

  • a keto group being part of a condensed ring system · CPC title

  • C07D303/14Primary

    by free hydroxyl radicals · CPC title

  • a keto group being part of a condensed ring system · CPC title

Patent family

Related publications grouped by family.

External sources

Frequently asked questions

Answers are generated from the same data shown on this page.

What does patent US9562026B2 cover?
The present disclosure is generally directed to neuroactive substituted cyclopent[a]anthracenes as referenced herein, and pharmaceutically acceptable salts thereof, for use as, for example, an anesthetic, and/or in the treatment of disorders relating to GABA function and activity. The present disclosure is further directed to pharmaceutical compositions comprising such compounds.
Who is the assignee on this patent?
Univ Washington
What technology area does this patent fall under?
Primary CPC classification C07D303/14. Mapped technology areas include Chemistry & Metallurgy.
When was this patent published?
Publication date Tue Feb 07 2017 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
What related patents are in patentsdb?
We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).